Authors:
Karine Charrière
1
;
Jean Sebastien Guerrini-Chappuis
1
;
Bruno Wacogne
2
;
Alain Rouleau
3
;
Celine Elie-Caille
3
;
Christian Pieralli
3
;
Lionel Pazart
1
;
Pascal Morel
4
and
Wilfrid Boireau
3
Affiliations:
1
Besançon University Hospital, France
;
2
Besançon University Hospital and University of Franche-Comté, France
;
3
University of Franche-Comté, France
;
4
French Blood Transfusion Center, France
Keyword(s):
Blood transfusion, Lab-on-chip, Microarray, Nanobiotechnology, Surface functionalization, Biosensor, Bedside test, ABO compatibility, Crossmatch.
Related
Ontology
Subjects/Areas/Topics:
Biocomputing and Biochips
;
Biomedical Engineering
;
Biomedical Instruments and Devices
;
Biomedical Sensors
Abstract:
Before each transfusion of red blood cell concentrate, a final ABO compatibility test is carried out at the patient's bedside on a piece of card and interpreted visually. Despite this ultimate test, transfusion accidents still occur due to group incompatibility, which can be lethal. In order to improve this test, we have developed a specific device based on microarrays for the validation of a smart and safe transfuser in the context of critical transfusional situations. This miniaturized device incorporates a biochip to analyze ABO compatibility in order that the hemagglutination reaction of red blood cells with IgMs in solution be replaced by specific capture and concentration of IgMs on microarrays. Results indicate that a specific immunocapture is obtained with globular concentrates and with different total blood. Smarttransfuser is a smart device developed in collaboration with the French Blood Transfusion Center for the optimization at the patient’s bedside of an ultimate test p
rior to transfusion.
(More)